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Female mice lacking Pald1 exhibit 
endothelial cell apoptosis and 
emphysema
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Paladin (Pald1, mKIAA1274 or x99384) was identified in screens for vascular-specific genes and is a 
putative phosphatase. Paladin has also been proposed to be involved in various biological processes 
such as insulin signaling, innate immunity and neural crest migration. To determine the role of paladin 
we have now characterized the Pald1 knock-out mouse in a broad array of behavioral, physiological 
and biochemical tests. Here, we show that female, but not male, Pald1 heterozygous and homozygous 
knock-out mice display an emphysema-like histology with increased alveolar air spaces and impaired 
lung function with an obstructive phenotype. In contrast to many other tissues where Pald1 is restricted 
to the vascular compartment, Pald1 is expressed in both the epithelial and mesenchymal compartments 
of the postnatal lung. However, in Pald1 knock-out females, there is a specific increase in apoptosis and 
proliferation of endothelial cells, but not in non-endothelial cells. This results in a transient reduction 
of endothelial cells in the maturing lung. Our data suggests that Pald1 is required during lung vascular 
development and for normal function of the developing and adult lung in a sex-specific manner. To our 
knowledge, this is the first report of a sex-specific effect on endothelial cell apoptosis.
Paladin or Pald1 is a phosphatase-domain containing protein and we have identified it in two independent 
screens for novel regulators of angiogenesis and vascular function1,2. Pald1 expression is prominent in developing 
endothelial cells during early embryonic development and, in certain vascular beds, Pald1 expression shifts to 
mural cells as the vasculature matures, e.g. in the CNS3. Furthermore, Pald1 was also found in hematopoietic 
cells and other non-vascular cells, such as neural crest cells3,4. A role of Pald1 as a regulator for neural crest cell 
formation and migration in the chick embryo has been shown by morpholino knock-down experiments. It was 
suggested that Pald1 would not require any catalytic activity for its role in neural crest migration since mutation 
of the putative catalytic cysteine to serine still affected neural crest migration after over expression4.
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Pald1 has also been shown to negatively regulate expression and phosphorylation of the insulin receptor, as 
well as phosphorylation of its downstream target kinase Akt in cell culture, even though no phosphatase activity 
could be detected in vitro5. Pald1 has therefore been proposed to be a pseudo-phosphatase, and as such been 
implicated to indirectly regulate cell signaling5–7. However, others have predicted that Pald1 can possess catalytic 
activity, even though this have not been shown experimentally yet8. Furthermore, Pald1 has been suggested to 
affect another type of receptor signaling, acting as a negative regulator of Toll-like receptor 99.
While there is a strong expression of Pald1 in both the prenatal and adult lung3, its role in lung develop-
ment or function is unknown. A central role for angiogenesis has been proposed for lung diseases like chronic 
obstructive pulmonary disease (COPD) and emphysema10. COPD is a chronic progressive disease characterized 
by clinical symptoms such as dyspnea and coughing, due to obstruction of the airways. COPD is a major cause 
of death worldwide and it is estimated that COPD will become the third leading cause of death by 202011,12. 
COPD is frequently accompanied by emphysema, i.e. the destruction of the alveolar walls and the consequen-
tial dilation of the distal airways10. Alterations of mRNA and protein expression of vascular endothelial growth 
factor A (VEGF-A) and its receptor VEGF receptor 2 (VEGFR2) are associated with patients exhibiting COPD 
and emphysema13. Experimental disruption of VEGF-A/VEGFR2 signaling has also been shown to be sufficient 
to induce emphysema and COPD-like changes in mice and rats through apoptosis14–16. There are sex-specific 
differences in COPD and emphysema in humans where subsets of women develop more severe emphysema than 
men. Female smokers with early onset COPD or severe emphysema have smoked significantly less than their 
male counterparts17. It has also been shown that female mice develop earlier and more severe emphysema than 
male mice in response to cigarette smoke18. However, the mechanisms responsible for this apparent sex-linkage 
remain unclear.
Here we describe the phenotype of Pald1+/− and Pald1−/− mice19,20 and characterize lung defects linking Pald1 
to sex-specific endothelial cell apoptosis, development of emphysema and COPD-like changes in females. To our 
knowledge, this is the first report of a sex-specific effect on endothelial cell apoptosis.
Results
Pald1−/− mice exhibit an obstructive lung phenotype. In order to characterize the Pald1−/− mouse, 
we performed a wide array of behavioral, physiological and biochemical tests at the German Mouse Clinic 
(GMC). Although most of the results turned out normal for Pald1−/− mice (Table S1 and Figure S1), it was note-
worthy that female, but not male, Pald1−/− mice exhibited increased lung volumes and compliance and decreased 
resistance, which are changes also observed in elastase-induced emphysema mouse model21 (Table 1).
Paladin is expressed broadly in the adult lung. We have previously shown that Pald1 protein is abun-
dant in the mesenchymal compartment of embryonic lungs and that Pald1 is also highly expressed in the adult 
lung3. Single cell sorting and sequencing from mouse embryonic lung strongly supports the conclusion that Pald1 
is exclusively expressed in endothelial cells during embryonic development22,23.
To begin to understand the role of Pald1 in postnatal lung development and function, we mapped Pald1 expres-
sion in detail. We analyzed the expression at three distinct time points during postnatal development and in the 
adult, postnatal day 5 (P5), 4 and 19 weeks of age as it covers main aspects of postnatal development of the major gas 
exchange unit of the lungs – the alveoli. The tremendous increase in gas exchange surface that occurs postnatally by 
formation of alveoli is accelerated from P5 until 2 weeks of age and peaks at 5–6 weeks. It is then stable until 40 weeks 
of age, and subsequently there is a gradual loss of alveoli. The decrease in alveolar septal thickness, that also facilitates 
gas exchange, continues from P5 until 4 weeks of age. Therefore, we decided to map the expression of Pald1 and 
assess the phenotype of Pald1−/− animals at P5, 4 and 19 weeks of age, to cover the dynamic process of postnatal lung 
development24. First we isolated single endothelial cells and pneumocytes type II from lungs using mT/mG reporter 
mice expressing Cre-recombinase under the endothelial Tie2 promoter and under the pneumocyte type II-specific 
surfactant protein C (SPC) promoter, respectively25,26. mRNA isolation and quantitative PCR for Pald1 showed that 
Pald1 is expressed in endothelial cells, but also in type II pneumocytes (Fig. 1a). To map the expression of Pald1 at 
cellular resolution, we took advantage of the LacZ reporter of Pald1 knock-out construct3. Murine Pald1 heterozy-
gous (Pald1LacZ/+) and homozygous mutant (Pald1LacZ/LacZ) lungs were harvested at postnatal day (P) 5, week 4 and 
week 19. The LacZ reporter indicated a broad expression of Pald1 in the murine lung in both males and females 
across all ages analyzed apart from bronchiolar epithelium. LacZ expression pattern was the same in Pald1LacZ/+ and 
Pald1LacZ/LacZ lungs (Fig. 1b and Figure S2). Combining LacZ staining with antibodies specific for each of the main 
cell types in the alveoli revealed that Pald1 can be detected at all stages in the endothelial cells forming the capillaries 
around the alveoli but is less frequently detected in the endothelium of larger vessels (Fig. 2, and Figure S3). Paladin 
was also detected in vascular smooth muscle cells, macrophages, pneumocytes type I and II and Platelet-derived 
Growth Factor Receptor α (PDGFRα)-positive mesenchymal cells (Fig. 2). However, the surfactant protein positive 
type II pneumocytes were not LacZ positive at P5.
Taken together, Pald1 mRNA and protein are strongly expressed in endothelial cells as well as in other cell 
types in the postnatal lung, except for bronchial epithelial cells.
Lack of Pald1 leads to enlarged distal airspaces in female mice. COPD in humans is often 
accompanied by emphysema, characterized by destruction of alveolar walls and distal airspace enlargement27. 
Histological analysis of Pald1 wild type and knock-out lungs revealed enlarged distal airspaces in female mice, 
but not in males, assessed by both blinded lung pathologist and quantification of mean linear intercept (MLI) 
(Fig. 3a–c). Increase in MLI, i.e. increase in distance between airway walls, was seen already at P5, at the end of 
the saccular stage and before alveolarization28. The distal airway dilation was still present at 4 and 19 weeks of 
age. Interestingly, we observed that female Pald1+/− mice also exhibited a significant increase in distal airspace 
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enlargement as quantified by MLI (Fig. 3d). However, no difference in alveolar septal thickness was detected 
(Pald1+/+ 2,67+/− 0,14 vs. Pald1−/− 2,48+/−0,07 µm3/µm2, P = 0,13).
Reduced number, increased apoptosis and proliferation of endothelial cells in female Pald1 
knock-out lungs. To further dissect the lung phenotype of female Pald1 knock-out mice, we used cell 
type-specific markers to assess the relative contribution in the lung. Cell type-specific markers for pneumocytes 
type I or II, macrophages or PDGFRα-positive cells did not reveal any differences of cell number between wild 
type and Pald1 knock-out mouse lungs over time (Fig. 4c–e and Figure S4). However, using the endothelial cell 
nuclei-specific marker Erg showed a reduction of endothelial cell number in the vascular compartment in females 
at 4 weeks of age by 14% (Fig. 4a and b).
Given the reduced number of endothelial cells at 4 weeks, we determined the frequency of apoptotic cells 
by cleaved caspase-3 (CC3) staining in both endothelial and non-endothelial cells in these lungs (Figure S5). 
There was a more than six-fold increase in apoptotic cells (0.75% ± 0.41% (SD) vs. 4.90% ± 0.76% CC3+ cells, 
p < 0.0001) in the endothelial compartment in female Pald1−/− compared to Pald1+/+ mice at 4 weeks of age. 
However, there were no differences in non-endothelial cell apoptosis or apoptosis comparing male wild type 
and knock-out mice. The increase in cleaved caspase-3 was still more than two-fold at both P5 and 19 weeks of 
age comparing wild type and knock-out Pald1 females (Fig. 5a and b). The enhanced endothelial apoptosis in 
female Pald1−/− was also accompanied by an increase of proliferation, as assessed by Ki-67 staining (Fig. 5c and 
Figure S5).
Sex-dependent protein expression differences in lung tissue. To begin to understand the mech-
anism of sex-specific phenotype in Pald1 knock-out lungs, we employed lung proteome analysis using mass 
spectrometry based proteomics29. We identified in total 10099 proteins at 1% protein false discovery rate, and 
8,635 proteins were quantified in all 16 lung samples (n = 4 per sex and genotype) from 4 weeks old mice. One 
female Pald1 knock-out sample was excluded from further analyses because of contamination as described in 
Female Male
Pald1+/+ (n = 6) Pald1−/− (n = 6) p-value Pald1+/+ (n = 7) Pald1−/− (n = 5) p-value
Median Median Median Median
[25%; 75%] [25%; 75%] [25%; 75%] [25%; 75%]
Body weight (g)
26.2 25.6 0.623 34.9 33.4 0.093
[24.4, 27.7] [23.6, 27.4] [34.1, 36.4] [32.8, 33.0]
Tidal volume (ml)
0.21 0.22 0.056 0.19 0.20 0.374
[0.21, 0.21] [0.22, 0.22] [0.18, 0.21] [0.20, 0.20]
Inspiratory capacity (ml)
0.695 0.885 0.026 0.871 1.340 0.026
[0.650, 0.755] [0.832, 0.982] [0.650, 0.755] [1.320, 1.253]
Expiratory Reverse Volume (ml)
0.26 0.29 0.323 0.24 0.26 0.425
[0.25, 0.29] [0.28, 0.30] [0.21, 0.26] [0.24, 0.28]
Vital Capacity (ml)
0.97 1.17 0.026 1.23 1.09 0.779
[0.90, 1.01] [1.12, 1.29] [0.90, 1.46] [1.12, 1.29]
Functional Residual Capacity (ml)
0.295 0.310 0.370 0.325 0.295 0.980
[0.290, 0.308] [0.292, 0.328] [0.329, 0.369] [0.275, 0.365]
Residual Volume (ml)
0.025 0.035 0.649 0.029 0.056 0.649
[0.020, 0.053] [0.030, 0.040] [0.025, 0.035] [0.030, 0.040]
Total lung capacity (ml)
1.005 1.190 0.022 1.472 1.695 0.096
[0.962, 1.032] [1.137, 1.302] [1.362, 1.532] [1.137, 1.859]
Forced Vital Capacity (ml)
0.895 1.065 0.026 1.099 1.160 0.323
[0.828, 0.925] [1.015, 1.175] [0.828, 1.125] [1.015, 1.175]
Forced Expiratory Volume in 100 ms 
(ml)
0.885 1.030 0.028 1.058 1.097 0.507
[0.802, 0.915] [0.982, 1.145] [0.976, 1.129] [0.872, 1.201]
Peak Expiratory Flow (ml/sec)
30.1 30.7 0.141 33.6 31.7 0.092
[30.1, 30.5] [30.6, 30.9] [33.1, 34.5] [30.8, 32.7]
Static lung compliance (ml/cm H2O)
0.050 0.070 0.039 0.056 0.053 0.384
[0.050, 0.058] [0.063, 0.070] [0.051, 0.059] [0.051, 0.055]
Dynamic lung compliance (ml/cm H2O)
0.02 0.03 0.015 0.04 0.03 0.370
[0.02, 0.02] [0.03, 0.03] [0.03, 0.05] [0.03, 0.03]
Resistance (cm H2O/ml/sec)
1.40 1.27 0.013 0.98 1.11 0.652
[1.35, 1.45] [1.23, 1.31] [0.96, 1.11] [1.01, 1.31]
Table 1. Functional lung tests in 20-week old Pald1+/+ and Pald1−/− mice. Lung function was assessed by 
a forced maneuver system and a Fine-Pointe RC system. Differences between genotypes were evaluated by 
Wilcoxon test. Data are presented as median values ± interquartile range.
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Materials and Methods. Hierarchical clustering based on the expression of all proteins showed that the major 
factor for clustering is sex, and not genotype (Fig. 6a). Three proteins including Pald1 showed significantly altered 
expression between wild type and knock-out mice in a sex-independent manner. Hpgd (hydroxyprostaglandin 
Figure 1. Paladin has a broad expression in the postnatal lung. (a) Endothelial cells and pneumocytes type II 
were isolated from lungs of mT/mG mice expressing endothelial-specific Tie2-Cre (left) or pneumocyte type 
II-specific SPC-Cre (right). Q-PCR of sorted single cells indicates Pald1 mRNA expression in both endothelial 
cells and non-endothelial cells, including pneumocytes type II, both at 3 weeks and 3 months of age. Expression 
was normalized to 18 S RNA. (b) Pald1 LacZ reporter activity (blue) is detected in Pald1LacZ/LacZ mice, 5 days, 4 
weeks and 19 weeks after birth. LacZ is broadly expressed in the lung tissue, except for the bronchial epithelium, 
which shows no reporter activity (arrow). Scale bar = 200 µm.
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Figure 2. Paladin is expressed both in the epithelial and mesenchymal compartment of the postnatal lung (4 
weeks). (a–e) Combined X-gal (black) and immunofluorescence staining of Pald1LacZ/LacZ mice show Pald1 LacZ 
expression in the vasculature, i.e. endothelial cells in capillaries (a) but to a lesser extent in endothelial cells of 
larger blood vessels (b) as indicated by Erg staining (endothelial cell nuclei, green). In large blood vessels LacZ 
expression can be detected in vascular smooth muscle cells (c, α-smooth muscle actin, red). Paladin LacZ 
reporter is also active in pneumocytes type II (d, SPC, green) and pneumocytes type I/II (e, cytokeratin, red). 
Scale bar = 20 µm.
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dehydrogenase 15 (NAD)), showed higher expression in knock-out lungs than wild type, which was confirmed 
by Western blot (Fig. 6b and Figure S6). In addition, Mycbp2, MYC binding protein 2, as well as Pald1 was signif-
icantly down regulated (Figure S7). The most differentially expressed protein between wild type male and female 
lungs was HSD17B7, a protein essential for cholesterol biosynthesis and with the capacity to catalyze conversion 
of estrone to estradiol30. There were no statistically significant protein expression changes that were specific to 
female knock-out mice, after correction for multiple testing.
Discussion
Several independent groups have identified Pald1 as a vascular enriched gene1,2,31 and we have previously shown 
that Pald1 is expressed in both endothelial and mural cells in the vasculature3.
Extensive phenotypic screening revealed morphological and functional lung defects in female Pald1−/− mice. 
This was accompanied by increased distal air spaces and elevated apoptosis and proliferation exclusively in the 
endothelial compartment of female mice. It is tempting to speculate, that Pald1 has a unique role in the vascu-
lature of the lung, as this is where we observe the strongest phenotype, even though the expression of Pald1 is 
broader and we cannot exclude that the increased endothelial turnover is secondary to alteration in other cell 
types.
Figure 3. Pald1−/− mice show reduced complexity of the lung tissue. (a,b) Dark field images of distal airspace 
from 4 weeks old female Pald1 wild type (a) and knock-out animals (b), suggest a general airspace enlargement 
in the Pald1 knock-out lungs. Scale bars = 200 µm. (c) Quantification of interseptal alveolar distance using 
Mean Linear Intercept (MLI) of hematoxylin-eosin stained lung tissue at P5 (n = 3), 4 (n = 5) and 19 weeks 
(n = 4) shows increased air spaces in female knock-out animals at all stages, but was particularly increased at 4 
weeks. ANOVA per age group: P5 p < 0.0001; 4 weeks p = 0.0002; 19 weeks p = 0.0004. Pald1−/− was compared 
to Pald1+/+ of the same sex within each age group. (d) MLI of Pald1 wild type, heterozygous and knock-out 
female mice at the indicated ages. ANOVA per age group: 4 weeks p = 0.0001, 19 weeks p = 0.0007. Pald1−/− 
and Pald1+/− were compared to Pald1+/+ within each age group. Error bars: SD, *p ≤ 0.05, ***p ≤ 0.001, 
****p ≤ 0.0001.
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A central role for endothelial cell apoptosis in the development of emphysema has been proposed. This is 
based on both the correlation of increased endothelial cell apoptosis and down regulation of VEGF in human 
patients exhibiting emphysema13, and experimental evidence in animal models. Genetic ablation of VEGF-A 
in the lung using adenoviral Cre led to endothelial and non-endothelial cell apoptosis, without a compensatory 
increase in proliferation16. Inhibition of VEGFRs using either low molecular weight kinase inhibitors or specific 
VEGFR2 (but not VEGFR1) blocking antibodies was also sufficient to trigger alveolar apoptosis and develop-
ment of emphysema in mice and rats14,15. In addition, direct induction of lung endothelial cell apoptosis using an 
endothelial-homing peptide triggers development of emphysema32, suggesting that alveolar structures cannot be 
maintained without endothelial cells, as well as that endothelial cell apoptosis in the lung culminates in emphy-
sema. Comparison of MLI measurements in the above-mentioned VEGF-A/VEGFR2 targeted mice and rats 
shows that the emphysema development in Pald1−/− female mice is comparable to what is seen in those models. 
However, alterations of VEGF and VEGFR levels were not the reason to emphysema in the Pald1 knock-out mice 
as no differences in VEGFA or VEGFR2 protein levels were detected in the proteomic analysis, or by western blot.
Figure 4. Pald1−/− show a decrease in the endothelial cell population at 4 weeks. (a–e) Quantification of the 
relative proportion of endothelial cells (a,b, Erg, n = 3–5), pneumocytes type II (c, SPC, n = 3), pneumocytes 
type I/II (d, cytokeratin, n = 3), and macrophages (e, CD68, n = 3–7). The specific cell type contribution was 
unaltered in Pald1−/− mice except for a 15% decrease of the endothelial cell population at 4 weeks in Pald1−/− 
mice. Scale bar = 20 µm, Error bars: SD, t-test between genotypes of each age group. ***p ≤ 0.001.
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The increase in distal airspace in female Pald1 knock-out mice is stable from early postnatal stage to 19 weeks 
of age. The mechanism of airspace enlargement must be distinct from emphysematous development in adult 
humans as it occurs already before alveolar septation and is non-progressive. Despite this, further studies into 
this phenotype, might provide additional information on what type of cellular changes and biochemical pathways 
that can lead to the end stage phenotype that we refer to as emphysema. Further studies will also be necessary 
to pinpoint the mechanism whereby Pald1 regulates endothelial cell survival and proliferation in a sex-specific 
fashion. The proteomics data showed that sex, but not genotype, was the most significant factor for differen-
tial protein expression. This is consistent with the accumulating evidence regarding sex differences and lung 
biology33. Somewhat surprisingly, no specific protein expression differences were detected between female wild 
type and knock-out lungs. However, Hpgd, the major enzyme for degradation of prostaglandins, showed higher 
expression in all knock-out lungs compared to wild type, irrespective of sex. Given that prostaglandin signaling 
is abundant and important for lung and vascular function as well as angiogenesis34, it could be speculated that 
prostaglandin signaling is associated with the emphysema phenotype, but that the Pald1−/− males are somehow 
protected. The lack of significant protein changes between female wild type and knock-out lungs, despite of the 
morphological differences and endothelial apoptosis observed at the time point analyzed, could be due to several 
reasons including sensitivity of the proteomics screen, use of complex tissue containing several cell types and/or 
due to time point of analysis. Even though we observe the greatest morphological changes at 4 weeks of age, the 
potential protein expression differences causing those changes might have occurred earlier.
Paladin was previously identified as a negative regulator of insulin signaling by in vitro screening for 
FOXO1A-driven reporter gene expression using a human cDNA library5. We detected a minor reduction in the 
ability to clear glucose from the blood stream in male mice as assessed by an intraperitoneal glucose tolerance 
test (Table S1). However, this is in contrast to the reported negative effect of Pald1 on insulin receptor signaling in 
cells. Further studies will be needed to determine the significance of this finding.
It was reported that Pald1 modulated the expression of key regulatory genes in neural crest development, and 
plasmid mediated over expression and morpholino-based knock-down of Pald1 delayed neural crest migration 
in the chick embryo4. Even though we have noted a prominent expression of Pald1 in migrating neural crest cells 
during embryonic development3, we have not noted any differences in neural crest derived tissues such as cardiac 
outflow tract, melanocytes, cranial bones or myelination in adult Pald1−/− mice. However, a transient role of 
Pald1 in neural crest migration during development has not been assessed.
Figure 5. Increased apoptosis and proliferation of endothelial cells in Pald1 knock-out female lungs. (a,b) 
Quantification of cleaved caspase-3 positive (CC3+) cells in 4 and 19-week old lungs revealed a significant 
increase in the number of cleaved caspase-3 positive endothelial cells (Erg positive) at 4 weeks of age and at 
19 weeks in female (a, n = 3–4), but not in male Pald1−/− mice (b, n = 3–4). There was no significant increase 
in non-endothelial cells (Erg negative) at both 4 and 19 weeks. (c,d) Quantification of Ki67 positive cells in 4 
and 19-week old lungs revealed an increased number of Ki67-positive endothelial cells (Erg positive) in female 
(c, n = 3–4), but not in male Pald1−/− mice (d, n = 3–4). There was no significant increase in non-endothelial 
cells (Erg negative) at both 4 and 19 weeks. Error bars: SD, t-test between genotypes within each age group. 
* = p ≤ 0.05, **** = p ≤ 0.0001.
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Taken together, our comprehensive description of the Pald1−/− mouse revealed that the putative phosphatase 
Pald1 plays a role in the development and function of the lung, and specifically in female pulmonary endothelial 
cell survival and proliferation. Further studies are necessary to address how the lack of Pald1 leads to endothelial 
cell apoptosis and proliferation, and how that is related to the emphysema phenotype in a sex-specific manner.
Materials and Methods
Paladin nomenclature and mouse model. Paladin is encoded by Pald1 (phosphatase domain contain-
ing, paladin 1, also known as x99384 or mKIAA1274) in mice. C57BL/6 mice with constitutive deletion for Pald1 
(Exon 1–18 replaced by a LacZ reporter cassette) have been generated3 and backcrossed for 10 generations. ROSA 
mT/mG × Tie2-Cre mice35 were generated as previously described25. ROSA mT/mG mice (Jackson Stock 007576) 
were crossed to Sftpc-Cre26 to generate ROSA mT/mG × Sftpc-Cre. All animal experiments were performed in 
accordance with the relevant laws and institutional guidelines and were approved by the Uppsala University 
board of animal experimentation. At the GMC mice were maintained in IVC cages with water and standard 
mouse chow according to the GMC housing conditions and German laws. All tests performed at the GMC were 
approved by the responsible authority of the district government of Upper Bavaria, Germany.
FACS and quantitative PCR. Isolation of single cells from ROSA mT/mG × Tie2-Cre and ROSA mT/
mG × Sftpc-Cre lungs by FACS, mRNA extraction and quantitative PCR was done as previously described25.
Western blot analysis. Snap frozen lungs from 2, 3 and 22-week old mice were lysed in 20 mM HEPES, 
150 mM NaCl, 1% NP40, 1x protease inhibitor cocktail (Roche), homogenized with Tissue Tearor (BioSpec 
Figure 6. Proteomics data overview and significantly differentially expressed proteins. (a) Proteomics reveals 
sex-dependent protein expression differences in lung tissue. The heatmap shows proteome data overview of 
8635 proteins with overlapping quantification in all 4 weeks of age lung samples using hierarchical clustering. 
Columns and rows represent lung samples and proteins, respectively. The samples are labels as sex_genotype_
ID. The major factor for clustering is sex, and not genotype. (b) Boxplot of the three significantly differentially 
expressed proteins. The y-axis shows the ratios to the pool. For each gene, the ratios to the pool in the wild type 
group (WT) and knock-out group (KO) are plotted in the boxplot, respectively.
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Products) and sonicated six times for 5 sec at 200 W (Bioruptor, diagenode). Tissue lysates were incubated for one 
hour at 4 °C with rotation, and centrifuged at 21’100 g for 20 min at 4 °C. Protein concentration was measured 
with the BCA protein detection kit (Thermo Fisher Scientific). Lung lysates were denatured in sample buffer (Life 
Technologies) and proteins were separated on a 4–12% BisTris polyacrylamide gel (Novex by Life Technologies). 
Proteins were transferred to an Immobilon-P PVDF membrane (Millipore) using the XCell II™ Blot Module 
(Novex by LifeTechnologies). The membrane was blocked with 5% skimmed milk in TBS 0.1% Tween and incu-
bated with rabbit anti-Pald1 (1:1000; Atlas Antibodies, HPA017343) or goat anti-actin (1:1000, Santa Cruz, 
sc-1615) antibodies overnight at 4 °C. Membranes were washed in TBS 0.1% Tween and incubated with horse-
radish peroxidase (HRP) conjugated secondary anti-rabbit (1:10’000, GE Healthcare) and anti-goat antibodies 
(1:10’000, Invitrogen), respectively. Membranes were washed in TBS 0.1% Tween and developed using ECL prime 
(GE Healthcare). Luminescence signal was detected by the ChemiDoc MP system (BioRad).
X-gal staining and immunohistochemistry of lung sections. Lungs were inflated and fixed intratra-
cheally with 4% PFA. The trachea was tied under pressure, and the lung was fixed for 2 h in 4% PFA at 4 °C. For 
histochemical analysis, paraffin sections of fixed lungs were dehydrated gradually in a series of 70% ethanol to 
xylene and soaked in paraffin (for 6 h in total) prior to embedding. Paraffin sections (6 µm) were deparaffinized 
using xylene, rehydrated in graded alcohol series (99.6% to 70% ethanol) and rinsed in distilled water. For H&E 
staining, sections were immersed sequentially in hematoxylin and eosin solutions (Histolab). Stained sections 
were dehydrated (70% ethanol to 99.6% ethanol, xylene) and mounted in PERTEX mounting media (Histolab). 
Interalveolar septal wall distance was measured by the mean linear intercept (MLI). Images from H&E stained 
lung sections were acquired on a Nikon light microscope (Nikon Eclipse 80i, Nikon digital camera DXM 1200) at 
a 400x magnification. The MLI was obtained by dividing the length of a line drawn across the lung section by the 
total number of intercepts encountered in 10 lines per picture. Twenty-five images per section, and two sections 
per lung, were analyzed. One section was from the inferior lobe and another one from the superior lobe.
For frozen lung sections, lungs were collected and fixed as described. After overnight incubation in 30% 
sucrose in PBS, lung sections of 5–10 µm were cut, blocked (3% BSA, 0.1% Triton x-100, 5% Normal Donkey 
serum [Jackson Immunoresearch], 5% Normal Mouse serum [Invitrogen] in PBS) and stained with rabbit 
anti-ERG (1:100, Abcam, ab92513), mouse anti-ERG (1:100, Abcam, ab140520), mouse anti-αSMA (1:100, 
Sigma, C6198), rabbit anti-prosurfactant Protein C (1:100, Abcam, ab40879), mouse anti-cytokeratin (1:100, 
Sigma, P2871), rat anti-CD68 (1:100, AbD serotec, MCA1957), rabbit anti-cleaved caspase 3 Ab-5 (1:3000, 
Neomarkers, RB-1611-P1), and mouse anti-ki67 (1:100, Dako, M7240) in combination with appropriate 
fluorophore-coupled secondary antibodies. Images were obtained with the Zeiss LSM700 confocal microscope, 
63x objective and analyzed by ImageJ. For x-gal staining, frozen lung sections were post-fixed in 0.2% PFA for 
10 min on ice, rinsed in PBS with 2 mM MgCl2 and permeabilized in detergent rinse (2 mM MgCl2, 0.01% sodium 
deoxycholate, 0.02% Nonidet P-40, PBS) for 10 min on ice, prior to overnight staining at 37 °C with 1 mg/ml x-gal 
(Promega) diluted in staining solution (detergent rinse containing 5 mM potassium ferricyanide, 5 mM potas-
sium ferrocyanide). Sections were washed twice for 10 min in detergent rinse, followed by PBS.
Statistical analysis of data sets of two groups was done by Student’s t-test and of three or more groups by 
one-way ANOVA using GraphPad Prism6.
Lung function analysis. Lung function analysis were performed as previously reported36. Briefly, lung 
function was assessed by a forced maneuver system and a Fine-Pointe RC system (Buxco Research Systems; 
Wilmington, NC, USA).
Statistical analyses were performed using R-scripts (version 3.0.2, Foundation of Statistical Computing, 
Vienna, Austria) implemented in the database (MausDB). Differences between genotypes were evaluated by 
Wilcoxon test. Statistical significance was assumed at p < 0.05. Data are presented as median values ± interquar-
tile range.
Proteome analysis. Mouse lung samples were lysed by SDS and prepared for mass spectrometry analysis 
using a modified version of the FASP protocol29. Peptides were labelled with TMT10plex reagent according to 
the manufacturer’s protocol (Thermo Scientific) and separated by immobilized pH gradient - isoelectric focusing 
(IPG-IEF) on 3–10 strips as described previously29. Extracted peptide fractions from the IPG-IEF were separated 
using an online 3000 RSLCnano system coupled to a Thermo Scientific Q Exactive. MSGF + Percolator in the 
Galaxy platform was used to match MS spectra to the Ensembl 82 mouse protein database37.
One of the samples in Pald1 knock-out females was excluded from further analyses because it is highly likely 
that squamous epithelium could have contaminated the sample; protein expression pattern was completely dif-
ferent from others and some proteins specific to squamous epithelial cells had been detected. The remaining 
quantified proteomics data were processed in R software. To identify differentially expressed genes between dif-
ferent groups (knock-out group versus controls, male versus female), student’s t test was used and multiple test 
correction was implemented using the false discovery rate method38. Heatmap analysis was performed using 
the pheatmap packages in R software. The genes were clustered using Pearson correlation distance and the sam-
ples were clustered using Euclidean distance. The average linkage cluster method was used to build the cluster 
dendrogram.
Data Availability. Mass spectrometry proteomics data is deposited to jPOSTrepo39 with the dataset identifier 
JPST000225 & PXD005625.
All other data generated or analyzed during this study are included in this published article (and its 
Supplementary Information files).
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